These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35565344)

  • 1. An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients' Age: A Retrospective Cohort Study.
    Massafra R; Bove S; La Forgia D; Comes MC; Didonna V; Gatta G; Giotta F; Latorre A; Nardone A; Palmiotti G; Quaresmini D; Rinaldi L; Tamborra P; Zito A; Rizzo A; Fanizzi A; Lorusso V
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological Aspects and Quantitative Assessment of Ki67 as Prognostic Factors in Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study.
    Niță I; Nițipir C; Toma ȘA; Limbău AM; Pîrvu E; Bădărău IA; Suciu I; Suciu G; Manolescu LSC
    Medicina (Kaunas); 2020 Nov; 56(11):. PubMed ID: 33182401
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer.
    Xiao Y; Zhang S; Hou G; Zhang X; Hao X; Zhang J
    Tumour Biol; 2014 Mar; 35(3):2035-45. PubMed ID: 24096546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
    J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Delpech Y; Wu Y; Hess KR; Hsu L; Ayers M; Natowicz R; Coutant C; Rouzier R; Barranger E; Hortobagyi GN; Mauro D; Pusztai L
    Breast Cancer Res Treat; 2012 Sep; 135(2):619-27. PubMed ID: 22890751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
    Fasching PA; Heusinger K; Haeberle L; Niklos M; Hein A; Bayer CM; Rauh C; Schulz-Wendtland R; Bani MR; Schrauder M; Kahmann L; Lux MP; Strehl JD; Hartmann A; Dimmler A; Beckmann MW; Wachter DL
    BMC Cancer; 2011 Nov; 11():486. PubMed ID: 22081974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
    Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer.
    Klintman M; Bendahl PO; Grabau D; Lövgren K; Malmström P; Fernö M;
    Mod Pathol; 2010 Feb; 23(2):251-9. PubMed ID: 19935641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.
    Carbognin L; Sperduti I; Fabi A; Dieci MV; Kadrija D; Griguolo G; Pilotto S; Guarneri V; Zampiva I; Brunelli M; Orvieto E; Nortilli R; Fiorio E; Parolin V; Manfrin E; Caliò A; Nisticò C; Pellini F; Scarpa A; Pollini GP; Conte P; Tortora G; Bria E
    Breast; 2017 Oct; 35():21-26. PubMed ID: 28628772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammaglobin-A, VEGFR3, and Ki67 in Human Breast Cancer Pathology and Five Year Survival.
    Baker E; Whiteoak N; Hall L; France J; Wilson D; Bhaskar P
    Breast Cancer (Auckl); 2019; 13():1178223419858957. PubMed ID: 31263371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy.
    Tan S; Fu X; Xu S; Qiu P; Lv Z; Xu Y; Zhang Q
    Pathol Oncol Res; 2021; 27():1609972. PubMed ID: 34987312
    [No Abstract]   [Full Text] [Related]  

  • 15. The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women.
    Kim J; Han W; Jung SY; Park YH; Moon HG; Ahn SK; Lee JW; Kim MK; Kim JJ; Lee ES; You TK; Kang HS; Lee ES; Ro J; Lee JE; Nam SJ; Yim YH; Park IA; Noh DY
    Ann Surg Oncol; 2015 Oct; 22(11):3481-8. PubMed ID: 25652052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
    Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
    J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer.
    Chen C; Zhang Y; Huang Z; Wu J; Huang W; Zhang G
    Cancer Biol Med; 2019 Aug; 16(3):575-586. PubMed ID: 31565486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic relevance of Ki67 expression in primary male breast cancer: determination of cut-off points by different evaluation methods and statistical examinations.
    Erices-Leclercq M; Lubig S; Förster F; Förster R; Baldus S; Rudlowski C; Schröder L
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):441-447. PubMed ID: 33991247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
    Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
    Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.